An article in the Sept. 26, 2003, issue of BioWorld Today should have said Neurobiological Technologies Inc. licensed use patents for memantine (Namenda) from Children's Hospital at Harvard University in the early 1990s for diabetic neuropathy, age-related dementia and Huntington's disease, and developed it for those indications. Lundbeck A/S markets the product in Alzheimer's disease throughout most of Europe, while Merz Pharmaceuticals GmbH co-markets it in the German-speaking countries. Also, the article should have said Ronny Kraft, spokesman for NTI, said Namenda "seemingly" is superior to Pfizer Inc.'s Aricept regarding efficacy and side effects.

Editor's note: The correction will be made in BioWorld online.

No Comments